Who Paid My Doc
Kelly Schultz
Nurse Practitioner, Primary Care Phoenix, AZ Nurse Practitioner
NPI 1023499860 CMS profile 10466473
4555 E Mayo Blvd, Phoenix, AZ 85050
General payments
$960
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Kelly Schultz of Phoenix, AZ is reported in the CMS Open Payments database as having received $960 across 33 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 70th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $206 | 5 | |
| 2024 | General | $69 | 3 | |
| 2023 | General | $189 | 7 | |
| 2022 | General | $117 | 7 | |
| 2021 | General | $379 | 11 |
Beside peers
- Kelly Schultz
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Kelly Schultz were reported at $206. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Kelly Schultz | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $379 | $137 | $39–$445 | $132 |
| 2022 | $117 | $139 | $44–$421 | $149 |
| 2023 | $189 | $163 | $53–$481 | $160 |
| 2024 | $69 | $176 | $54–$511 | $164 |
| 2025 | $206 | $169 | $51–$499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 59 drugsPart D claims
1,775
Drug cost
$102,915
Branded share of claims
12.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 45 | $49,329 | |
| Myrbetriq Mirabegron | Brand | 26 | $14,625 | |
| Arexvy Rsvpref3 Antigen/As01e/Pf | Brand | 19 | $5,820 | |
| Carbidopa-Levodopa Carbidopa/Levodopa | Brand | 33 | $2,723 | |
| Synthroid Levothyroxine Sodium | Brand | 26 | $2,474 | |
| Levothyroxine Sodium | Generic | 141 | $2,136 | |
| Temazepam | Generic | 22 | $1,907 | |
| Fentanyl | Generic | 16 | $1,397 | |
| Atorvastatin Calcium | Generic | 100 | $1,319 | |
| Trazodone Hcl | Generic | 68 | $996 |
The 10 drugs with the highest cost, of 59 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 115 billing codesPaid by Medicare
$354,771
Medicare patients
509
Services billed
7,811
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 55% | |
| Heart failure | 34% | |
| Atrial fibrillation | 34% | |
| Osteoporosis | 33% | |
| Chronic kidney disease | 31% | |
| Ischemic heart disease | 29% | |
| Depression | 28% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Puraply am, per square centimeter Q4196 | Office | 15 | 650 | $52,965 |
| Sarscv2 vac 30mcg trs-suc im 91320 | Office | 257 | 283 | $36,944 |
| Injection, denosumab, 1 mg J0897 | Office | 18 | 1,500 | $29,436 |
| Vaccine for influenza for injection into muscle 90653 | Office | 205 | 205 | $16,773 |
| Pcv20 vaccine im 90677 | Office | 17 | 17 | $4,965 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 14 | 32 | $26 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 12 | 22 | $13 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 17 | 45 | $4 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
33 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Primary Care in Arizona
Trey Powrzanas
Nurse Practitioner, Primary Care · Phoenix, AZ
Christine Rocks-Lopez
Nurse Practitioner, Primary Care · Phoenix, AZ
Elena Klimova
Nurse Practitioner, Primary Care · Phoenix, AZ
Albert Villafania
Nurse Practitioner, Primary Care · Phoenix, AZ
Daniela Haimov
Nurse Practitioner, Primary Care · Phoenix, AZ
Lea Nickolas
Nurse Practitioner, Primary Care · Avondale, AZ
Related records
Nurse Practitioner, Primary Care in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.